Resources>Blog>12th Immuno-Oncology Summit 2024 – Philadelphia: Highlights and Event Recap

12th Immuno-Oncology Summit 2024 – Philadelphia: Highlights and Event Recap

Biointron 2024-08-14 Read time: 3 mins

imx-og-banner.jpg

The 12th Immuno-Oncology Summit 2024 was held in Philadelphia, PA on August 7-9, 2024. The annual event serves as a vital platform for exchanging high-quality research and fostering collaboration in the ever-evolving landscape of immuno-oncology. Topics discussed included: 

  • Bispecific Antibodies for Cancer Immunotherapy 

  • Advances in CAR T Therapy 

  • Therapeutic Cancer Vaccines 

  • Emerging Tech for IO Targeting and Discovery 

  • Emerging Cell-Based Immunotherapies 

  • Tumor Microenvironment 

 

→ Biointron’s Highlighted Points: 

1. Bispecific Breakthroughs: Reimagining Design, Manufacturing, & Safety 

  • Creating cancer-specific neoantigens by exploiting covalent inhibitors and targeting them with bispecific antibodies unites targeted and immune therapies. (NYU Grossman School of Medicine) 

  • Adapting T cell engagers to target the massive intracellular proteome has been challenging due to low cell-surface density antigen presentation. Geometry plays an important role in efficiently targeting low density cell-surface pMHC, rather than avidity. (AstraZeneca) 

  • The humanized trispecific antibody TAVO412, has two distinct anti-EGFR nanobody domains, an anti-cMet Fab arm, and an anti-VEGF ScFv. It infiltrates solid tumor stromal barriers to treat patients with gastric, TNBC, and pancreatic cancer subtypes. (Tavotek Biotherapeutics) 

2. Breaking Barriers in CAR T: Engineering, Synergistic Strategies, & Beyond 

  • iPSC-derived CD8ab CAR T cells: Early TCR or CAR expression promotes the acquisition of an innate phenotype, which is averted by timed and calibrated CAR expression. (Memorial Sloan Kettering Cancer Center) 

  • Proposed precision medicine approach for B-cell malignancies using CAR T cells involves engineering T cells with a CAR that recognizes the IGHV4-34 B Cell Receptor to specifically eliminate malignant B-cells. (University of Pennsylvania) 

  • Integrated Circuit T Cells (ICTs), a novel engineered T cell design, incorporates multiple functionalities for a promising approach to achieve more precise targeting of solid tumors. (Arsenal Bio) 

3. Innovative Vaccine Strategies to Advance Cancer Immunotherapy 

  • A novel personalized therapeutic mRNA lipid nanoparticle vaccine shows efficacy in brain, neck, and oral cancer preclinical and clinical trials. (Cleveland Clinic) 

  • Long-read sequencing allows us to resolve a broader spectrum of protein altering genomic events which serve as a richer basis for neoantigen discovery, versus short-read exome sequencing. (University of North Carolina at Chapel Hill) 

  • Non-invasive mRNA delivery via stabilized, lung-optimized lipid nanoparticles for pulmonary applications, and the enhancement of immune responses in mRNA vaccines through integration of multiple, novel adjuvants. (Broad Institute) 

4. Unlocking Precision IO: Innovative Tools, Targets, & Solutions 

  • CRISPR screening in immunosuppressive tumor-associated macrophages (TAMs) identifies novel targets that reprogram TAMs into immunostimulatory macrophages, leading to abrogation of established tumors. (Weill Cornell Medicine) 

  • Predicting therapy outcomes with autoantibody biomarkers in melanoma has shown promising results, holding great potential to personalize cancer therapy for more effective and safer treatments (NYU Grossman School of Medicine) 

  • Casdozokitug, a potent and selective anti-IL-27 antibody has demonstrated immune activation and single-agent tumor response, overcoming PD-1 resistance in clinical trials. (Coherus Biosciences 

event copy.jpg

Thank you for visiting us at our booth at Immuno-Oncology Summit 2024 to learn about our services! We had a great time connecting with you and understanding how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com!

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.